The CIS-treated group showed a significant upregulation of caspase-3 (p ≤ 0.001) and BAX (p ≤ 0.01) gene expression and showed no significant change in Bcl-2 gene expression as compared to the EQ + CIS-treated group (Figure 4D–F). This evidence concerns the gene BCL2 and in situ carcinoma.